Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: Synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model

Journal of Medicinal Chemistry

Volumn 48, Issue 8, 2005, Pages 2972-2984

  Handratta, Venkatesh D ^a   Vasaitis, Tadas S ^a   Njar, Vincent C O ^a   Gediya, Lalji K ^a   Kataria, Ritesh ^a   Chopra, Pankaj ^a   Newman Jr , Donnell ^a   Farquhar, Rena ^a   Guo, Zhiyong ^a   Qiu, Yun ^a   Brodie, Angela M H ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 (1H BENZIMIDAZOL 1 YL)ANDROSTA 4,16 DIEN 3 ONE; 17 IODOANDROSTA 5,16 DIEN 3BETA OL; 3BETA ACETOXY 17 CHLORO 16 FORMYLANDROSTA 5,16 DIENE; 3BETA HYDROXY 17 (1H BENZIMIDAZOL 1 YL)ANDROSTA 5,16 DIENE; 3BETA HYDROXY 17 (5 PYRIMIDYL)ANDROSTA 5,16 DIONE; ABIRATERONE; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIONE; ANTIANDROGEN; BICALUTAMIDE; CYTOCHROME P450 17 INHIBITOR; ENZYME INHIBITOR; FINASTERIDE; FLUTAMIDE; KETOCONAZOLE; METRIBOLONE; PYRAZINE DERIVATIVE; PYRROLE DERIVATIVE; STEROID 5ALPHA REDUCTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING COMPETITION; CANCER INHIBITION; CONTROLLED STUDY; CROSS COUPLING REACTION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MALE; MOUSE; NONHUMAN; ORCHIECTOMY; PROSTATE CANCER; REACTION ANALYSIS; SCID MOUSE; TUMOR XENOGRAFT;

ANDROGEN ANTAGONISTS; ANDROSTADIENES; ANIMALS; ANTINEOPLASTIC AGENTS; AZOLES; BENZIMIDAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; ISOENZYMES; MALE; MICE; MICE, SCID; MUTATION; PROSTATIC NEOPLASMS; PYRAZINES; RADIOLIGAND ASSAY; RECEPTORS, ANDROGEN; STEROID 17-ALPHA-HYDROXYLASE; STRUCTURE-ACTIVITY RELATIONSHIP; TESTOSTERONE 5-ALPHA-REDUCTASE; TISSUE DISTRIBUTION; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 20944449560     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040202w     Document Type: Article

References (38)

1. (a) Jemal, A.; Tiwari, R. C.; Murray, T.; Ghafoor, A.; Samuels, A.; Ward, E.; Feuer, E. J.; Thun, M. J. Cancer Statistics, 2004. CA Cancer J. Clin. 2004, 54, 8-29.
2. (b) American Cancer Society. Cancer Facts and Figures 2003; American Cancer Society: Atlanta, GA.
3. McConnell, J. D. Physiological basis of endocrine therapy for prostatic cancer. Urol. Clin. North Am. 1991, 18, 1-13.
4. Bruchovsky, N.; Wilson, J. D. The conversion of testosterone to 5α-androstan-17β-ol-3-one by rat prostate in vivo and in vitro. J. Biol. Chem. 1968, 243, 2012-2021.
5. Huggins, C.; Stephens, R. C.; Hudges, C. V. Studies on prostatic cancer: 2. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg. 1941, 43, 209-212.
6. Denmeade, S. R.; Isaacs, J. T. A history of prostate cancer treatment. Nat. Rev. Cancer 2002, 2, 389-396.
7. Crawford, E. D.; Eisenberger, M. A.; McLeod, D. G.; Spaulding, J. T.; Benson, R.; Dorr, F. A.; Blumstein, B. A.; Davis, M. A.; Goodman, P. J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 1989, 321, 419-424.
8. Crawford, E. D.; Allen, J. A. Treatment of newly diagnosed state D2 prostate cancer with leuprolide and flutamide or leuprolide alone, Phase III: intergroup study 0036. J. Urol. 1992, 147, 417A.
9. Denis, L. Role of maximal androgen blockade in advanced prostate cancer. Prostate 1994, 5 (Suppl.), 17s-22s.
10. Mohler, J. L.; Gregory, C. W.; Ford, H. O., III; Kim, D.; Weaver, C. M.; Petrusz, P.; Wilson, E. M.; French, F. S. The androgen axis in recurrent prostate cancer. Clin. Cancer Res. 2004, 10, 440-448.
11. Chen, C. D.; Welsbie, D. S.; Tran, C.; Baek, S. H.; Chen, R.; Vessella, R.; Rosenfeld, G. M.; Sawyer, C. L. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004, 10, 33-39.
12. 17,20-lyase (CYP17): Potential agents for the treatment of prostate cancer. Curr. Pharm. Des. 1999, 5, 163-180.
13. 21scc: one enzyme with two actions: Hydroxylase and lyase, J. Steroid Biochem. Mol. Biol. 1991, 40, 527-532.
14. Trachtenberg, J.; Halpern, N.; Pont, A. Ketoconazole: A novel and rapid treatment for advanced prostatic cancer. J. Urol. 1983, 130, 152-153.
15. Muscato, J. J.; Ahmann, K. M.; Johnson, W.; Wilding, W.; Monaghan, G.; Schlossman, D. M. Optimal dosing of ketoconazole and hydrocrtisone leads to long responses in hormone refractory prostate cancer. Proc. Am. Assoc. Cancer Res. 1994, 13, 22 (Abstract).
16. Small, E. J.; Baron, A. D.; Fippin, L.; Apodaca, D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J. Urol. 1997, 157, 1204-1207.
17. O'Donnell, A.; Judson, I.; Dowsett, M.; Raynaud, F.; Dearnaley, D.; Mason, M.; Harland, S.; Robbins, A.; Halbert, G.; Nutley, B.; Jarman, M. Hormonal impact of the 17α-hydroxylase/C17, 20-lyase inhibitors abiraterone acetate (CB7630) in patients with prostate cancer. Br. J. Cancer 2004, 90, 2317-2325.
18. Long, B. J.; Grigoryev, D. N.; Nnane, I. P.; Liu, Y.; Ling, Y.-Z.; Brodie, A. M. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Cancer Res. 2000, 60, 6630-6640.
19. Nicolaou, K. C.; Pfefferkorn, J. A.; Roecker, J. A.; Cao, G.-Q.; Barluenga, S.; Mitchell, H. J. Natural product-like combinatorial libraries based on privileged structures. 1. General principles and solid-phase synthesis of benzopyrans. J. Am. Chem. Soc. 2000, 122, 9939-9953. "Privileged structures", a term originally introduced by Evans et al. (J. Med. Chem. 1988, 31, 2235-2246) to describe structural motifs capable of interacting with a variety of unrelated molecular targets.
20. Nicolaou, K. C.; Pfefferkorn, J. A.; Roecker, J. A.; Cao, G.-Q.; Barluenga, S.; Mitchell, H. J. Natural product-like combinatorial libraries based on privileged structures. 1. General principles and solid-phase synthesis of benzopyrans. J. Am. Chem. Soc. 2000, 122, 9939-9953. "Privileged structures", a term originally introduced by Evans et al. (J. Med. Chem. 1988, 31, 2235-2246) to describe structural motifs capable of interacting with a variety of unrelated molecular targets.
21. (a) Haidar, S.; Ehmer, P. B.; Hartmann, R. W. Novel steroidal pyrimidyl inhibitors of P450 17 (17α-hydroxylase/C17-20-lyase). Arch. Pharm. Med. Chem. 2001, 334, 373-374.
22. (b) Haidar, S.; Ehmer, P. B.; Barassin, S.; Batzl-Hartmann, C.; Hartmann, R. W. Effects of novel 17α-hydroxylase/C17,20-lyase (P45017, CYP17) inhibitors on androgen biosynthesis in vitro and in vivo. J. Steroid Biochem. Mol. Biol. 2003, 84, 555-562.
23. 17α), Bioorg. Med. Chem. Lett. 1996, 6, 2777-2782.
24. 17α): Potential agents for the treatment of prostate cancer, J. Med. Chem. 1998, 41, 902-912.
25. Potter, G. A.; Hardcastle, I. R.; Jarman, M. A convenient, large-scale synthesis of abiraterone acetate [3β-acetoxy-17(3-pyridyl)-androsta-5, 16-diene], a potential new drug for the treatment of prostate cancer. Org. Prep. Proc. Int. 1997, 29, 123-128.
26. Choshi, T.; Yamada, S.; Sugino, E.; Kuwada, T.; Hibino, S. Total synthesis of Grossularines-1 and -2. J. Org. Chem. 1995, 60, 5899-5904.
27. Grigoryev, D. N.; Kato, K.; Njar, V. C. O.; Long, B. J.; Ling, Y.-Z.; Wang, X.; Mohler, J.; Brodie, A. M. H. Cytochrome P450c17-expressing Escherichia coli as a first-step screening system for 17α-hydroxylase-C17,20-lyase inhibitors. Anal. Biochem. 1999, 267, 319-330.
28. Grigoryev, D. N.; Long, B. J.; Nnane, I. P.; Njar, V. C. O.; Liu, Y.; Brodie, A. M. H. Effects of new 17α-hydroxylase/C17,20-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo. Br. J. Cancer 1999, 81, 622-630.
29. Jefcoat, C. R. Measurement of substrate and inhibitor binding to microsomal cytochrome P450 by optical difference spectroscopy. Methods Enzymol. 1978, 52, 258-279.
30. Picard, F.; Barassin, S.; Mokhtarian, A.; Hartmann, R. W. Synthesis and evaluation of 2′-substituted 4-(4′-carboxy- or 4′- carboxymethylbenzylidene)-N-acylpiperidines: Highly potent and in vivo active steroid 5α-reductase type 2 inhibitors. J. Med. Chem. 2002, 45, 3406-3417.
31. Nnane, I. P.; Njar, V. C. O.; Brodie, A. M. H. Pharmacokinetic profile of 3β-hydroxy-17-(1H-123-triazol-1-yl)androsta-5,16-diene (VN/87-1), a potent androgen synthesis inhibitor in mice. J. Steroid Biochem. Mol. Biol. 2001, 71, 145-152.
32. Handratta, V. D.; Jelovac, D.; Long, B. J.; Kataria, R.; Nnane, I. V.; Njar, V. C. O.; Brodie, A. M. H. Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model. J. Steroid Biochem. Mol. Biol. 2004, 92, 155-165.
33. Kim, O.; Jiang, T.; Xie, Y.; Guo, Z.; Chen, H.; Qiu, Y. Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells. Oncogene 2004, 23, 1838-1844.
34. Zhang, J.; Thomas, T. Z.; Kasper, S.; Matusik, R. J. A Small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in Vitro and in Vivo. Endocrinology 2000, 141, 4698-4710.
35. Thompson, T. A.; Wilding, G. Androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol in human prostate carcinoma cells. Mol. Caner Ther. 2003, 2, 797-803.
36. Eichenberger, T.; Trachtenberg, J.; Toor, P.; Keating, A. Ketoconazole: A possible direct cytotoxic effect on prostate carcinoma cells. J. Urol. 1989, 141, 190-191.
37. Kline, K. A.; Reiter, R. E.; Redula, J.; Moradi, H.; Zhu, X. L.; Brothman, A. R.; Lamb, D. J.; Marcelli, M.; Belldegrun, A.; Witte, O. N.; Sawyer, C. L. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat. Med. 1997, 3, 402-408.
38. Tindall, D.; McFarland Horne, F.; Hruszkewycz, A.; Mohla, S.; Shuman, M.; Wang, Z.; Kantoff, P. Symposium on androgen action in prostate cancer. Cancer Res. 2004, 64, 7178-7180.